Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Post by attila9on Jun 10, 2004 11:55am

166 Views

Post# 7595854

So all the check in box

guys knew there was going to be a news release in a couple of days (last week) or this week at the latest did they.I didn't tell you guys anything you already didn't know hey Spiff. It's good to see that even if your one of the check your in box guys you recieve the same crock of SH## unrelyable information that the rest of us recieve when you contact the company.Of course they still have one day left this week to make good on their statement of a news release.Place your bets, your more likely to win some money than you are to make some money with the information this company provides it's investors.Gee didn't someone say they were known to stretch the truth just a tad??Just bloody marvelous this bunch is!!!JMHO of course.snicker, snicker, snicker.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading